American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Incyte Genomics Inc

INCY Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

INCY historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of INCY by members of U.S. Congress

Politician Type Traded
Ro Khanna House / D Purchase $1,001 - $15,000 May 15, 2026
Ro Khanna House / D Purchase $1,001 - $15,000 Mar 30, 2026
Ro Khanna House / D Sale $1,001 - $15,000 Mar 10, 2026
Ro Khanna House / D Purchase $1,001 - $15,000 Jan 29, 2026
Ro Khanna House / D Purchase $1,001 - $15,000 May 19, 2025
Robert Bresnahan House / R Sale $1,001 - $15,000 May 15, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Feb 19, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Jan 17, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Nov 15, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 02, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 02, 2024
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 Apr 23, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Mar 25, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Dec 04, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Oct 10, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Oct 02, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Sep 06, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Jun 29, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Jun 26, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 May 19, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Mar 14, 2023
Daniel S. Goldman House / D Sale $1,001 - $15,000 Mar 06, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Feb 02, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Dec 06, 2022
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 07, 2021
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Dec 22, 2020
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Sep 16, 2020
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 Apr 07, 2020
Ro Khanna House / D Purchase $1,001 - $15,000 Feb 11, 2020
Ro Khanna House / D Sale $1,001 - $15,000 Jan 08, 2020
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 23, 2019
Ro Khanna House / D Sale $1,001 - $15,000 Dec 17, 2018
Ro Khanna House / D Sale $1,001 - $15,000 Dec 10, 2018
Shelley Moore Capito Senate / R Sale (Full) $1,001 - $15,000 Nov 12, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 25, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 17, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 02, 2018
Ro Khanna House / D Sale $1,001 - $15,000 Jul 24, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Jun 15, 2018
Ro Khanna House / D Sale $1,001 - $15,000 May 08, 2018
Ro Khanna House / D Sale $1,001 - $15,000 May 04, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 03, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Mar 06, 2018
INCY Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
INCY Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
INCY Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in INCY holdings by institutional investors

Insider Trading

Quarterly net insider trading by INCY's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $750,000 Jul 20, 2026 Issue: Medicare/Medicaid
  • $480,000 Apr 20, 2026 Issue: Medicare/Medicaid
  • $530,000 Jan 20, 2026 Issue: Medicare/Medicaid
  • $330,000 Oct 20, 2025 Issue: Medicare/Medicaid
  • $520,000 Jul 21, 2025 Issue: Medicare/Medicaid
  • $240,000 Apr 21, 2025 Issue: Medicare/Medicaid
  • $350,000 Feb 21, 2025 Issue: Medicare/Medicaid
  • $220,000 Oct 21, 2024 Issue: Medicare/Medicaid
  • $300,000 Jul 22, 2024 Issue: Medicare/Medicaid
  • $460,000 Apr 22, 2024 Issue: Medicare/Medicaid
  • $360,000 Oct 20, 2023 Issue: Medicare/Medicaid
  • $220,000 Jul 20, 2023 Issue: Medicare/Medicaid
  • $180,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid
  • $220,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid
  • $200,000 Jul 21, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid
  • $280,000 Apr 20, 2022 Issue: Medicare/Medicaid
  • $110,000 Jan 21, 2022 Issue: MEDICARE/MEDICAID
  • $190,000 Oct 20, 2021 Issue: MEDICARE/MEDICAID
  • $500,000 Jul 20, 2021 Issue: MEDICARE/MEDICAID
  • $200,000 Apr 20, 2021 Issue: MEDICARE/MEDICAID
  • $50,000 Jan 21, 2021 Issue: Health Issues
  • $50,000 Jan 20, 2021 Issue: None
  • $20,000 Jan 19, 2021 Issue: None
  • $50,000 Oct 20, 2020 Issue: Health Issues
  • $50,000 Oct 20, 2020 Issue: MEDICARE/MEDICAID
  • $50,000 Jul 20, 2020 Issue: MEDICARE/MEDICAID
  • $50,000 Jul 20, 2020 Issue: Medicare/Medicaid
  • $50,000 Apr 27, 2020 Issue: MEDICARE/MEDICAID
  • $50,000 Apr 17, 2020 Issue: Medicare/Medicaid
  • $30,000 Jan 21, 2020 Issue: MEDICARE/MEDICAID
  • $30,000 Jan 18, 2020 Issue: Medicare/Medicaid
  • $20,000 Mar 26, 2003 Issue: Copyright/Patent/Trademark
  • $20,000 Aug 22, 2002 Issue: Copyright/Patent/Trademark
  • $20,000 Mar 14, 2002 Issue: Copyright/Patent/Trademark
  • $60,000 Feb 20, 2002 Issue: None
  • $20,000 Sep 28, 2001 Issue: Copyright/Patent/Trademark
  • $60,000 Feb 15, 2000 Issue: Medical/Disease Research/Clinical Labs
  • $40,000 Aug 16, 1999 Issue: Medical/Disease Research/Clinical Labs
Revolving Door

Former government officials who have lobbied for INCY

14 former government officials from 11 congressional offices at 5 lobbying firms have lobbied for INCY, most recently Jul 20, 2026.

  • J. Dennis Hastert
    Darren Willcox House Asst. for Policy, Speaker Dennis Hastert; Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss; House Rules Comm. Assoc., Subcommittee Staff Director Formerly with J. Dennis Hastert · W STRATEGIES, LLC · Jul 20, 2026
  • Jon C. Porter
    Alanna Temme House Legislative Director, U.S. Representative Jon Porter Formerly with Jon C. Porter · LMH STRATEGIC SOLUTIONS · Apr 17, 2026
  • Martha Roby
    Sophie Khanahmadi House Legislative Asst., Rep. Martha Roby; Legislative Asst., Rep. Lee Terry; Staff Asst./LC, Senator Jeff Sessions Formerly with Martha Roby · LMH STRATEGIC SOLUTIONS · Apr 17, 2026
  • Charles E. Schumer
    Matthew Fuentes Senate New LA - Senate Democratic Minority Leader Sen. Chuck Schumer; LA -Senate Democratic Majority Leader Sen. Chuck Schumer; Legislative Aide - Sen. Chuck Schumer; Research Assistant - Senate Finance Committee (Sen. Ron Wyden) Formerly with Charles E. Schumer · AVENUE SOLUTIONS · Jul 21, 2025
  • John Cornyn
    Emily Kirlin Senate New Mbr Servs Dir, Sen. John Cornyn (2016-2018); Whip Liaison, Sen. Cornyn (2013-2016); Whip Liaison, Sen. Jon Kyl (2011-2013); Int Comms, Sen. Lamar Alexander (2011); Comms Assist, Sen. Alexander (2009-2010); Mbr Guest Rels, Sen. Alexander (2008-2009) Formerly with John Cornyn · TIBER CREEK GROUP · Apr 18, 2025
  • Tom Price
    John Twomey House New Chief of Staff, HHS Office of the Asst. Sec. for Legislation (2019-2021); Policy Adviser, HHS (2017-2019); Special Asst., Office of the Secretary, HHS (2017); Staff Assistant, Rep. Tom Price (2015-2017); Intern, Rep. Doug Collins (2015) Formerly with Tom Price · TIBER CREEK GROUP · Apr 18, 2025
  • Jennifer Barblan House New Chief Oversight Counsel, Counsel, House Energy and Commerce Committee; Senior Counsel, Counsel, House Oversight and Government Reform Committee; Staff Assistant, House Judiciary Committee. Formerly Chief Oversight Counsel, Counsel, House Energy and Commerce Committee; Senior Co · INCYTE CORPORATION · Feb 21, 2025
  • Scott H. Peters
    Daniel Zawitoski House New Chief of Staff, Rep. Scott Peters (2018-2023); Legislative Director, Rep. Scott Peters (2015-2018); Legislative Assistant, Rep. Scott Peters (2014-2015); Legislative Correspondent, Rep. Scott Peters (2013-2014). Formerly with Scott H. Peters · TIBER CREEK GROUP · Oct 16, 2023
See all 14 on the Revolving Door dashboard
Corporate Lobbying

INCY Estimated quarterly lobbying spending

Revenue Breakdown

INCY Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
INCY Income Statement
INCY Balance Sheet
INCY Cash Flow
U.S. Patents

New INCY patent grants

  • Patent Title: Piperidin-4-yl azetidine derivatives as jak1 inhibitors Jun. 19, 2018
  • Patent Title: Cyclopropylamines as lsd1 inhibitors Jun. 12, 2018
  • Patent Title: Crystalline forms of a pi3k inhibitor Jun. 05, 2018
  • Patent Title: Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors Jun. 05, 2018
  • Patent Title: Pyrrolotriazine compounds as tam inhibitors May. 29, 2018
  • Patent Title: Pyrimidinones as pi3k inhibitors May. 22, 2018
  • Patent Title: Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors May. 22, 2018
  • Patent Title: 1h-pyrrolo[2,3,c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins May. 01, 2018
  • Patent Title: Amido compounds and their use as pharmaceuticals May. 01, 2018
  • Patent Title: Heterocyclic compounds as lsd1 inhibitors Apr. 17, 2018
  • Patent Title: Bicyclic azaheterocyclobenzylamines as pi3k inhibitors Apr. 17, 2018
  • Patent Title: Imidazotriazines and imidazopyrimidines as kinase inhibitors Apr. 17, 2018
  • Patent Title: Tricyclic heterocycles as bet protein inhibitors Apr. 10, 2018
  • Patent Title: Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders Apr. 03, 2018
  • Patent Title: Bipyrazole derivatives as jak inhibitors Mar. 27, 2018
  • Patent Title: Heterocyclic compounds useful as pim kinase inhibitors Mar. 20, 2018
  • Patent Title: Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as bet protein inhibitors Mar. 20, 2018
  • Patent Title: Secreted proteins Mar. 13, 2018
  • Patent Title: Tricyclic fused thiophene derivatives as jak inhibitors Mar. 06, 2018
  • Patent Title: Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines Mar. 06, 2018
  • Patent Title: Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors Feb. 13, 2018
  • Patent Title: Bicyclic heterocycles as fgfr4 inhibitors Feb. 13, 2018
  • Patent Title: Methods for detecting expression levels of human signal peptide-containing proteins (hspp) Feb. 06, 2018
  • Patent Title: Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as janus kinase inhibitors Jan. 30, 2018
  • Patent Title: Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 Jan. 23, 2018
  • Patent Title: Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor Jan. 23, 2018
  • Patent Title: Salts of a pim kinase inhibitor Jan. 09, 2018
  • Patent Title: Tricyclic heterocycles as bet protein inhibitors Dec. 26, 2017
  • Patent Title: Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors Dec. 26, 2017
  • Patent Title: Heterocyclic compounds and uses thereof Dec. 12, 2017
  • Patent Title: Tricyclic heterocycles as bet protein inhibitors Dec. 05, 2017
  • Patent Title: Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors Nov. 21, 2017
  • Patent Title: N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors Nov. 14, 2017
  • Patent Title: Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors Nov. 14, 2017
  • Patent Title: Processes of preparing a jak1 inhibitor and new forms thereto Oct. 31, 2017
  • Patent Title: Pyridineamine compounds useful as pim kinase inhibitors Oct. 31, 2017
  • Patent Title: Bicyclic heterocycles as fgfr4 inhibitors Oct. 31, 2017
  • Patent Title: Aza spiro alkane derivatives as inhibitors of metalloproteases Oct. 31, 2017
  • Patent Title: 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Oct. 17, 2017
  • Patent Title: Tricyclic fused thiophene derivatives as jak inhibitors Oct. 03, 2017
  • Patent Title: Tricyclic heterocycles as bet protein inhibitors Oct. 03, 2017
  • Patent Title: Triazolopyridines and triazolopyrazines as lsd1 inhibitors Sep. 12, 2017
  • Patent Title: Substituted pyrrolo[2,3-b]pyrazines as fgfr inhibitors Aug. 29, 2017
  • Patent Title: Bicyclic heterocycles as bet protein inhibitors Aug. 22, 2017
  • Patent Title: Process for the synthesis of a phosphoinositide 3-kinase inhibitor Aug. 15, 2017
  • Patent Title: Heterocyclylamines as pi3k inhibitors Aug. 15, 2017
  • Patent Title: Processes and intermediates for making a jak inhibitor Aug. 01, 2017
  • Patent Title: Processes and intermediates for making a jak inhibitor Jul. 25, 2017
  • Patent Title: Fused bicyclic 1,2,4-triazine compounds as tam inhibitors Jul. 18, 2017
  • Patent Title: Bicyclic heterocycles as fgfr4 inhibitors Jul. 18, 2017
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to INCY from public contracts

INCY News

Recent insights relating to INCY

CNBC Recommendations

Recent picks made for INCY stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in INCY

INCY Analyst Ratings

INCY Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
INCY Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $INCY stock a Buy, Sell, or Hold?

  • What is the price target for $INCY stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

INCY Top Shareholders
Shareholder
Shares Held
INCY Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $INCY stock?

  • Who owns the most shares of $INCY stock?

  • What funds own $INCY stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

INCY Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view INCY Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About INCY

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

  • Address Wilmington, DE
  • Market Cap 25.3 billion
  • Employees 2,844
  • Industrial Classification Services-Commercial Physical & Biological Research

Incyte Genomics Inc (INCY) Historical Stock Prices

Incyte Genomics Inc (INCY) closed at $124.64 on September 23, 2026. Over the past year its adjusted close ranged from $81.66 to $129.93. Daily prices go back to January 2, 2014, 3,200 trading days in all.

  • 1 month-2.61%
  • 3 months+14.92%
  • Year to date+26.19%
  • 1 year+47.43%
  • 3 years+114.53%
  • 5 years+80.64%
  • Max+143.29%
See every congressional and insider trade on the INCY price chart

Quiver Premium charts INCY's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 23, 2026 127.51 128.21 123.89 124.64 124.64 1,534,432
Sep 22, 2026 124.72 127.75 124.01 126.93 126.93 1,647,176
Sep 21, 2026 125.00 127.41 124.19 124.65 124.65 1,270,531
Sep 18, 2026 127.85 128.72 125.23 125.31 125.31 3,700,438
Sep 17, 2026 125.74 127.74 125.10 127.62 127.62 1,468,843
Sep 16, 2026 121.48 124.96 121.48 124.75 124.75 1,347,302
Sep 15, 2026 121.58 122.19 119.97 121.74 121.74 1,564,077
Sep 14, 2026 122.48 123.34 121.28 122.19 122.19 1,455,967
Sep 11, 2026 124.35 124.35 121.42 121.47 121.47 1,425,198
Sep 10, 2026 125.09 126.31 122.58 123.28 123.28 1,462,890
Sep 9, 2026 125.66 127.72 123.57 126.01 126.01 1,301,228
Sep 8, 2026 124.11 126.40 122.22 124.40 124.40 1,283,253
Sep 4, 2026 126.46 128.08 126.04 126.75 126.75 1,036,073
Sep 3, 2026 129.67 130.00 126.20 128.00 128.00 910,226
Sep 2, 2026 126.43 129.56 125.89 128.83 128.83 2,324,205
Sep 1, 2026 124.61 125.14 122.50 125.01 125.01 1,191,993
Aug 31, 2026 122.66 124.00 121.61 123.22 123.22 1,483,195
Aug 28, 2026 127.74 127.74 123.08 124.37 124.37 1,215,069
Aug 27, 2026 128.13 128.20 126.06 127.74 127.74 700,682
Aug 26, 2026 129.18 129.53 127.77 128.12 128.12 800,283
Aug 25, 2026 128.97 130.80 127.50 129.72 129.72 1,162,238
Aug 24, 2026 127.47 128.36 126.31 127.98 127.98 799,608
Aug 21, 2026 126.45 129.92 125.60 127.81 127.81 1,367,411
Aug 20, 2026 127.10 129.80 126.71 127.22 127.22 1,207,144
Aug 19, 2026 125.00 129.56 124.59 128.47 128.47 1,589,005
Aug 18, 2026 124.29 124.74 123.23 123.47 123.47 1,191,480
Aug 17, 2026 120.16 124.06 119.64 123.50 123.50 2,040,676
Aug 14, 2026 119.15 120.44 117.56 120.16 120.16 785,830
Aug 13, 2026 122.23 122.23 119.71 120.52 120.52 829,464
Aug 12, 2026 119.54 121.57 118.88 120.77 120.77 1,055,267
Aug 11, 2026 121.13 122.28 120.06 121.07 121.07 1,080,064
Aug 10, 2026 120.56 122.69 120.50 121.55 121.55 1,352,384
Aug 7, 2026 118.56 120.88 117.38 120.56 120.56 1,540,373
Aug 6, 2026 119.80 120.29 115.77 118.38 118.38 2,390,460
Aug 5, 2026 123.99 124.57 119.52 119.80 119.80 1,795,673
Aug 4, 2026 119.08 120.93 117.00 120.60 120.60 2,077,654
Aug 3, 2026 120.22 121.37 118.02 118.43 118.43 1,419,133
Jul 31, 2026 122.75 122.75 118.44 119.52 119.52 1,830,263
Jul 30, 2026 123.99 126.50 121.63 122.99 122.99 2,628,292
Jul 29, 2026 128.87 129.95 125.83 127.10 127.10 2,917,698
Jul 28, 2026 119.00 132.60 118.64 129.93 129.93 5,921,515
Jul 27, 2026 117.67 120.71 117.25 118.87 118.87 2,729,176
Jul 24, 2026 117.71 119.13 116.70 117.67 117.67 1,207,106
Jul 23, 2026 115.04 117.47 114.50 116.69 116.69 956,259
Jul 22, 2026 116.27 118.66 115.77 115.79 115.79 998,480
Jul 21, 2026 115.36 118.95 114.80 117.39 117.39 1,906,845
Jul 20, 2026 117.62 118.65 114.95 115.65 115.65 1,257,145
Jul 17, 2026 116.27 119.60 116.27 117.25 117.25 2,232,513
Jul 16, 2026 115.01 117.18 114.13 116.65 116.65 1,365,126
Jul 15, 2026 113.54 115.80 110.56 115.09 115.09 1,564,844
Jul 14, 2026 114.26 115.31 112.81 114.88 114.88 1,300,773
Jul 13, 2026 115.97 116.02 113.80 114.23 114.23 1,481,000
Jul 10, 2026 118.53 118.93 115.21 116.71 116.71 1,643,980
Jul 9, 2026 116.43 118.97 116.43 118.52 118.52 1,353,569
Jul 8, 2026 118.06 118.77 116.41 117.26 117.26 1,878,406
Jul 7, 2026 117.53 118.14 116.15 118.05 118.05 1,667,760
Jul 6, 2026 116.37 116.50 114.27 115.62 115.62 1,277,144
Jul 2, 2026 114.18 118.69 113.50 116.86 116.86 2,632,596
Jul 1, 2026 114.70 116.00 113.31 113.81 113.81 1,711,033
Jun 30, 2026 115.00 115.46 112.80 113.36 113.36 1,830,643
Jun 29, 2026 115.48 115.48 112.89 114.66 114.66 1,532,380
Jun 26, 2026 109.47 115.56 109.47 113.75 113.75 3,795,266
Jun 25, 2026 108.35 110.75 106.48 107.53 107.53 1,832,481
Jun 24, 2026 105.53 109.10 104.49 108.46 108.46 1,963,908
Jun 23, 2026 104.61 105.48 103.07 104.40 104.40 1,670,984
Jun 22, 2026 99.79 103.71 99.79 103.66 103.66 2,204,988
Jun 18, 2026 99.58 99.62 96.09 98.22 98.22 4,058,623
Jun 17, 2026 99.82 101.03 98.25 98.99 98.99 1,716,059
Jun 16, 2026 102.75 103.33 99.53 99.75 99.75 1,556,318
Jun 15, 2026 107.98 107.98 101.32 101.98 101.98 2,815,109
Jun 12, 2026 107.83 109.64 106.53 108.53 108.53 1,488,907
Jun 11, 2026 105.97 109.69 104.08 107.83 107.83 2,318,442
Jun 10, 2026 103.37 110.34 103.30 105.39 105.39 2,654,379
Jun 9, 2026 102.16 104.23 101.51 103.23 103.23 2,318,919
Jun 8, 2026 102.77 104.63 98.78 100.64 100.64 2,975,218
Jun 5, 2026 101.19 106.37 100.81 102.38 102.38 2,641,348
Jun 4, 2026 99.34 101.46 98.75 101.24 101.24 1,780,156
Jun 3, 2026 93.02 98.48 92.66 97.98 97.98 2,270,005
Jun 2, 2026 94.70 94.89 92.18 92.24 92.24 2,021,788
Jun 1, 2026 96.48 97.00 94.21 95.59 95.59 1,592,434
May 29, 2026 97.75 98.00 96.23 96.74 96.74 2,903,015
May 28, 2026 97.32 97.79 96.57 97.50 97.50 1,305,350
May 27, 2026 97.52 98.85 96.92 97.34 97.34 939,714
May 26, 2026 97.35 98.13 96.64 97.10 97.10 1,176,044
May 22, 2026 97.30 98.21 96.04 97.16 97.16 879,786
May 21, 2026 95.90 97.94 95.15 97.41 97.41 765,557
May 20, 2026 98.40 98.40 96.03 97.08 97.08 1,066,364
May 19, 2026 95.19 96.36 94.10 95.60 95.60 1,166,723
May 18, 2026 95.48 96.60 94.63 95.19 95.19 1,020,910
May 15, 2026 97.44 97.70 94.31 95.31 95.31 1,648,990
May 14, 2026 99.02 99.36 97.12 97.63 97.63 1,350,211
May 13, 2026 98.73 99.04 97.07 98.82 98.82 1,630,417
May 12, 2026 100.84 101.24 98.94 99.13 99.13 1,584,910
May 11, 2026 99.04 103.01 99.04 100.32 100.32 1,662,287
May 8, 2026 98.60 99.87 97.47 98.56 98.56 877,843
May 7, 2026 99.68 99.68 97.12 97.77 97.77 1,021,629
May 6, 2026 98.62 100.01 97.61 99.85 99.85 1,178,896
May 5, 2026 97.81 98.90 96.15 97.47 97.47 1,038,437
May 4, 2026 96.54 97.60 96.34 97.14 97.14 1,018,069
May 1, 2026 95.26 97.05 94.81 96.91 96.91 1,203,665
Apr 30, 2026 100.33 100.85 94.92 95.27 95.27 2,409,862
Apr 29, 2026 99.18 102.86 96.67 99.10 99.10 2,242,760
Apr 28, 2026 94.75 98.36 92.79 97.74 97.74 2,531,040
Apr 27, 2026 94.50 97.66 94.50 95.72 95.72 2,148,642
Apr 24, 2026 94.95 95.20 93.63 94.65 94.65 1,117,137
Apr 23, 2026 96.37 97.25 95.10 95.47 95.47 905,081
Apr 22, 2026 97.02 98.19 96.00 96.74 96.74 1,012,656
Apr 21, 2026 97.04 97.24 94.93 96.22 96.22 1,478,941
Apr 20, 2026 98.65 98.70 96.58 96.92 96.92 1,033,325
Apr 17, 2026 96.60 97.94 95.63 97.82 97.82 1,529,954
Apr 16, 2026 96.95 97.53 94.56 95.32 95.32 1,616,846
Apr 15, 2026 98.75 99.92 97.00 97.10 97.10 1,214,313
Apr 14, 2026 95.76 97.90 95.76 97.69 97.69 1,519,929
Apr 13, 2026 96.13 96.85 93.84 95.55 95.55 1,186,422
Apr 10, 2026 97.53 97.57 95.41 96.07 96.07 1,146,821
Apr 9, 2026 95.13 97.58 94.66 96.96 96.96 1,089,599
Apr 8, 2026 95.39 95.98 93.50 95.89 95.89 1,152,022
Apr 7, 2026 94.43 95.07 93.23 93.69 93.69 1,393,665
Apr 6, 2026 94.96 96.14 94.00 94.86 94.86 998,001
Apr 2, 2026 93.02 96.05 92.55 95.93 95.93 1,160,053
Apr 1, 2026 94.65 95.56 93.80 94.30 94.30 1,481,097
Mar 31, 2026 91.54 94.42 91.17 94.12 94.12 1,826,384
Mar 30, 2026 91.13 91.69 90.08 90.33 90.33 1,535,716
Mar 27, 2026 92.28 92.50 90.20 90.30 90.30 1,494,399
Mar 26, 2026 90.99 93.73 90.99 92.26 92.26 1,229,676
Mar 25, 2026 91.00 93.83 91.00 92.23 92.23 1,055,736
Mar 24, 2026 89.63 91.70 89.25 90.62 90.62 1,584,246
Mar 23, 2026 91.16 92.33 90.00 90.45 90.45 1,415,692
Mar 20, 2026 92.81 93.34 90.34 90.78 90.78 4,388,758
Mar 19, 2026 91.88 93.57 91.72 92.95 92.95 1,331,571
Mar 18, 2026 93.35 93.91 91.62 92.24 92.24 1,577,285
Mar 17, 2026 93.04 94.91 93.04 94.22 94.22 1,864,575
Mar 16, 2026 92.14 93.65 91.15 93.00 93.00 1,617,370
Mar 13, 2026 93.25 93.64 91.28 92.54 92.54 1,683,761
Mar 12, 2026 93.00 93.45 91.54 92.03 92.03 1,947,421
Mar 11, 2026 95.98 96.51 94.61 94.66 94.66 1,726,493
Mar 10, 2026 97.52 97.86 95.90 96.02 96.02 1,547,972
Mar 9, 2026 95.94 97.61 94.52 97.10 97.10 1,521,176
Mar 6, 2026 96.23 96.30 94.61 95.94 95.94 1,255,015
Mar 5, 2026 97.99 99.35 96.07 97.33 97.33 1,331,361
Mar 4, 2026 99.16 99.41 96.91 98.86 98.86 1,628,585
Mar 3, 2026 98.48 99.57 97.00 98.07 98.07 1,645,128
Mar 2, 2026 99.94 101.00 97.54 100.04 100.04 1,672,671
Feb 27, 2026 99.04 101.77 98.86 101.27 101.27 2,315,098
Feb 26, 2026 99.91 100.20 97.31 100.09 100.09 2,092,248
Feb 25, 2026 101.05 101.16 98.57 99.98 99.98 1,664,742
Feb 24, 2026 100.86 102.25 100.08 101.05 101.05 1,696,328
Feb 23, 2026 101.32 103.16 100.04 100.84 100.84 1,333,403
Feb 20, 2026 101.63 102.66 100.09 101.32 101.32 1,509,365
Feb 19, 2026 102.13 102.81 100.00 101.73 101.73 1,460,339
Feb 18, 2026 100.77 103.69 100.64 102.99 102.99 1,607,485
Feb 17, 2026 101.72 103.90 100.17 101.16 101.16 1,905,146
Feb 13, 2026 101.47 103.18 100.53 101.10 101.10 1,384,666
Feb 12, 2026 98.87 102.20 97.90 100.75 100.75 1,700,614
Feb 11, 2026 98.52 99.79 97.25 98.84 98.84 1,925,256
Feb 10, 2026 103.00 106.21 98.76 100.05 100.05 4,748,829
Feb 9, 2026 108.50 109.48 106.58 109.03 109.03 2,700,690
Feb 6, 2026 103.75 108.52 103.52 108.39 108.39 2,193,912
Feb 5, 2026 102.71 106.48 102.23 102.76 102.76 2,047,491
Feb 4, 2026 102.61 103.55 101.44 102.60 102.60 1,915,403
Feb 3, 2026 102.75 104.41 100.72 100.92 100.92 1,552,576
Feb 2, 2026 99.75 102.86 99.50 102.67 102.67 1,574,084
Jan 30, 2026 100.77 101.25 99.28 100.07 100.07 1,988,982
Jan 29, 2026 101.09 101.89 100.21 101.08 101.08 1,439,938
Jan 28, 2026 103.02 104.03 98.85 101.18 101.18 1,576,840
Jan 27, 2026 103.00 105.06 102.59 103.47 103.47 1,544,424
Jan 26, 2026 101.57 103.42 101.10 102.58 102.58 1,439,019
Jan 23, 2026 104.34 104.70 100.07 101.99 101.99 2,360,919
Jan 22, 2026 105.02 106.06 104.36 105.06 105.06 1,307,456
Jan 21, 2026 102.50 105.43 101.00 104.67 104.67 1,570,377
Jan 20, 2026 103.26 103.85 100.00 102.62 102.62 2,205,966
Jan 16, 2026 105.55 108.58 104.83 106.21 106.21 1,696,253
Jan 15, 2026 106.16 106.74 104.27 105.24 105.24 1,571,769
Jan 14, 2026 103.66 107.64 103.20 105.95 105.95 2,128,350
Jan 13, 2026 106.56 107.54 102.67 103.43 103.43 2,041,395
Jan 12, 2026 106.94 106.94 104.70 106.33 106.33 1,761,288
Jan 9, 2026 106.04 107.69 105.93 106.87 106.87 1,520,739
Jan 8, 2026 109.74 110.09 104.69 105.92 105.92 2,578,423
Jan 7, 2026 107.88 112.29 107.88 110.57 110.57 3,377,159
Jan 6, 2026 101.73 107.48 101.02 106.66 106.66 3,857,869
Jan 5, 2026 103.00 103.01 99.04 101.79 101.79 3,051,819
Jan 2, 2026 98.25 101.50 97.94 101.42 101.42 2,152,342
Dec 31, 2025 98.43 99.89 98.13 98.77 98.77 1,376,638
Dec 30, 2025 99.21 99.28 98.06 98.91 98.91 1,603,807
Dec 29, 2025 100.03 100.08 97.63 99.29 99.29 1,225,971
Dec 26, 2025 100.41 100.41 99.57 100.11 100.11 626,766
Dec 24, 2025 100.94 101.51 100.30 100.44 100.44 490,612
Dec 23, 2025 100.50 101.71 100.02 100.91 100.91 1,330,722
Dec 22, 2025 101.94 102.52 98.99 100.71 100.71 1,974,718
Dec 19, 2025 97.77 103.45 97.36 102.69 102.69 5,906,932
Dec 18, 2025 98.25 98.34 97.01 97.31 97.31 1,757,713
Dec 17, 2025 97.26 98.90 97.09 97.63 97.63 1,598,606
Dec 16, 2025 98.17 98.69 96.40 97.03 97.03 2,055,054
Dec 15, 2025 96.27 99.44 95.48 98.64 98.64 2,815,675
Dec 12, 2025 95.76 96.00 93.54 95.41 95.41 2,264,451
Dec 11, 2025 94.94 96.89 94.39 96.10 96.10 1,836,076
Dec 10, 2025 95.58 96.88 94.28 95.17 95.17 1,872,115
Dec 9, 2025 96.52 97.98 94.66 95.16 95.16 2,455,870
Dec 8, 2025 100.12 100.43 94.34 96.70 96.70 3,868,756
Dec 5, 2025 101.00 103.68 98.36 102.52 102.52 2,357,052
Dec 4, 2025 101.38 102.47 99.69 100.46 100.46 2,088,653
Dec 3, 2025 101.80 102.62 100.90 101.50 101.50 1,874,701
Dec 2, 2025 102.41 103.54 100.55 101.44 101.44 2,438,855
Dec 1, 2025 103.49 103.89 101.47 102.04 102.04 2,254,874
Nov 28, 2025 106.45 106.99 103.85 104.46 104.46 932,388
Nov 26, 2025 105.61 107.00 105.08 105.65 105.65 1,403,552
Nov 25, 2025 106.59 107.61 105.16 105.55 105.55 1,701,879
Nov 24, 2025 103.00 106.67 102.50 106.24 106.24 2,660,581
Nov 21, 2025 102.00 103.20 101.40 102.06 102.06 1,722,545
Nov 20, 2025 102.50 103.22 101.08 101.76 101.76 1,673,222
Nov 19, 2025 104.66 104.66 100.30 101.32 101.32 2,734,795
Nov 18, 2025 104.20 107.31 103.79 103.89 103.89 2,831,388
Nov 17, 2025 104.36 105.97 103.83 104.17 104.17 1,411,770
Nov 14, 2025 104.57 106.92 103.77 104.15 104.15 2,035,020
Nov 13, 2025 107.27 107.76 105.03 105.41 105.41 2,151,938
Nov 12, 2025 108.05 109.28 106.81 108.26 108.26 1,743,221
Nov 11, 2025 106.00 108.67 105.53 108.16 108.16 2,006,608
Nov 10, 2025 107.38 108.81 104.06 105.98 105.98 2,654,399
Nov 7, 2025 105.50 106.40 103.81 105.98 105.98 2,019,980
Nov 6, 2025 106.29 106.43 103.02 105.20 105.20 2,392,448
Nov 5, 2025 101.91 106.47 101.50 105.70 105.70 2,764,010
Nov 4, 2025 101.84 103.86 100.02 102.92 102.92 3,531,241
Nov 3, 2025 93.95 101.79 91.16 101.57 101.57 6,227,722
Oct 31, 2025 92.70 95.10 92.06 93.48 93.48 2,503,165
Oct 30, 2025 91.34 94.62 91.19 92.59 92.59 2,405,599
Oct 29, 2025 91.48 94.42 88.20 90.18 90.18 3,443,736
Oct 28, 2025 92.14 93.98 84.02 91.65 91.65 6,876,194
Oct 27, 2025 92.16 93.17 90.69 93.08 93.08 3,803,021
Oct 24, 2025 90.00 92.08 89.73 91.28 91.28 2,236,993
Oct 23, 2025 87.65 89.56 87.50 89.31 89.31 2,032,317
Oct 22, 2025 87.40 88.21 87.25 88.06 88.06 1,582,675
Oct 21, 2025 85.65 87.48 85.55 87.30 87.30 1,136,976
Oct 20, 2025 87.94 87.94 84.38 86.17 86.17 2,100,676
Oct 17, 2025 87.04 88.54 86.36 87.57 87.57 2,070,856
Oct 16, 2025 88.88 92.86 87.12 87.31 87.31 3,760,265
Oct 15, 2025 85.13 88.49 85.13 88.15 88.15 2,049,716
Oct 14, 2025 84.38 86.16 83.46 85.96 85.96 1,303,211
Oct 13, 2025 84.39 85.15 82.81 84.73 84.73 1,067,688
Oct 10, 2025 85.01 85.19 83.06 83.80 83.80 1,576,610
Oct 9, 2025 85.55 85.92 84.14 84.75 84.75 1,401,194
Oct 8, 2025 86.56 86.87 84.96 85.38 85.38 1,620,177
Oct 7, 2025 87.31 87.95 85.92 87.17 87.17 1,212,468
Oct 6, 2025 86.99 88.30 86.41 87.23 87.23 1,919,237
Oct 3, 2025 85.91 86.98 85.18 86.85 86.85 1,303,859
Oct 2, 2025 87.65 88.66 86.17 86.28 86.28 1,787,761
Oct 1, 2025 84.95 87.24 84.90 86.70 86.70 1,630,543
Sep 30, 2025 83.83 85.31 83.75 84.81 84.81 1,251,195
Sep 29, 2025 83.02 84.41 82.52 83.89 83.89 1,564,469
Sep 26, 2025 82.57 82.95 81.78 82.70 82.70 1,376,209
Sep 25, 2025 83.86 84.45 81.09 81.66 81.66 1,488,626
Sep 24, 2025 84.19 84.82 83.66 84.16 84.16 1,297,794
Sep 23, 2025 84.75 85.83 84.42 84.54 84.54 1,607,480

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Incyte Genomics Inc Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at INCY, per a recent SEC DEF 14A filing. We estimate that the median employee at INCYTE CORP is paid $255,918.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation